Open AccessAnticholinergic Burden, Polypharmacy, and Cognition in Parkinson’s Disease Patients with Mild Cognitive Impairment: A Cross-Sectional Observational Study
Author(s) -
Betül Sümbül Şekerci,
Başar Bılgıç,
Özge Pasin,
Murat Emre,
Haşmet Hanağası
Publication year - 2022
Publication title -
dementia and geriatric cognitive disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.026
H-Index - 110
eISSN - 1421-9824
pISSN - 1420-8008
DOI - 10.1159/000526863
Subject(s) - anticholinergic , polypharmacy , medicine , cognition , concordance , cross sectional study , dementia , anticholinergic agents , psychology , psychiatry , disease , pathology
Anticholinergic burden may be an important risk factor for the cognitive impairment. Especially in polypharmacy, even drugs with low anticholinergic effects may contribute to a significant anticholinergic burden. The drugs with anticholinergic effects are used in treatment of motor and nonmotor symptoms of Parkinson's disease (PD). Therefore, it is important to screen for polypharmacy and anticholinergic burden in PD patients with mild cognitive impairment (MCI).